Darifenacin
NDC product · U.S. Food and Drug Administration (openFDA) · United States
-
Product NDC
69097-431 -
Package NDC
69097-431-02 -
Package NDC
69097-431-05 -
Package NDC
69097-431-15 -
Application number
ANDA207664 -
SPL ID
99ca2704-b757-4f10-be5c-bd01dff69b10 -
SPL set ID
6e8470d1-c3e6-4644-b70a-aa47ddf79676 -
UNII
CR02EYQ8GV -
RxCUI
485421 -
RxCUI
485423
What the source publishes
- Labeler
- Cipla USA Inc.
- Active ingredients
- Darifenacin Hydrobromide
- Form
- TABLET, EXTENDED RELEASE
- Routes
- ORAL
- Administrative status
- present-in-source-snapshot
- Marketing status
- ANDA
- Product type
- HUMAN PRESCRIPTION DRUG
- Prescription
- Prescription or restricted
Names this record is found by
Complete source data
{
"name": "Darifenacin",
"splId": "99ca2704-b757-4f10-be5c-bd01dff69b10",
"labels": [
{
"setId": "6e8470d1-c3e6-4644-b70a-aa47ddf79676",
"labelUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e8470d1-c3e6-4644-b70a-aa47ddf79676",
"labelPdfUrl": "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=6e8470d1-c3e6-4644-b70a-aa47ddf79676"
}
],
"routes": [
"ORAL"
],
"labeler": "Cipla USA Inc.",
"finished": true,
"packaging": [
{
"sample": false,
"description": "30 TABLET, EXTENDED RELEASE in 1 BOTTLE (69097-431-02)",
"package_ndc": "69097-431-02",
"identifierStatus": "well-formed",
"marketing_start_date": "20160901"
},
{
"sample": false,
"description": "90 TABLET, EXTENDED RELEASE in 1 BOTTLE (69097-431-05)",
"package_ndc": "69097-431-05",
"identifierStatus": "well-formed",
"marketing_start_date": "20160901"
},
{
"sample": false,
"description": "1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (69097-431-15)",
"package_ndc": "69097-431-15",
"identifierStatus": "well-formed",
"marketing_start_date": "20160901"
}
],
"productId": "69097-431_99ca2704-b757-4f10-be5c-bd01dff69b10",
"useDomain": "unknown",
"dosageForm": "TABLET, EXTENDED RELEASE",
"productNdc": "69097-431",
"deaSchedule": null,
"genericName": "Darifenacin Hydrobromide",
"productType": "HUMAN PRESCRIPTION DRUG",
"listingStatus": "present-in-source-snapshot",
"targetSpecies": [],
"approvalStatus": "not-established-by-ndc-listing",
"labelAssociation": "openFDA-harmonized-set-ids; not a product-level approval match",
"marketingEndDate": null,
"activeIngredients": [
{
"name": "DARIFENACIN HYDROBROMIDE",
"strength": "7.5 mg/1"
}
],
"applicationNumber": "ANDA207664",
"marketingCategory": "ANDA",
"stateRestrictions": {
"status": "not-collected",
"observations": []
},
"useDomainEvidence": {
"basis": "unreviewed",
"field": null,
"value": null,
"version": 1,
"sourceId": "us.fda.ndc"
},
"marketingStartDate": "20160901",
"targetSpeciesStatus": "not-reported",
"prescriptionCategory": "prescription-or-restricted",
"harmonizedIdentifiers": {
"unii": [
"CR02EYQ8GV"
],
"rxcui": [
"485421",
"485423"
],
"spl_set_id": [
"6e8470d1-c3e6-4644-b70a-aa47ddf79676"
],
"manufacturer_name": [
"Cipla USA Inc."
],
"is_original_packager": [
true
]
},
"listingExpirationDate": "20261231"
}
Read this record from your own software
The same record, with every field and its provenance, is one request away. An API key is free and works immediately.
curl -G "https://api.medifontis.com/v1/drugs/record" \
-H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
--data-urlencode "country=us" \
--data-urlencode "sourceId=us.fda.ndc" \
--data-urlencode "id=us:fda:ndc:69097-431_99ca2704-b757-4f10-be5c-bd01dff69b10"